Loading organizations...

§ Private Profile · London, United Kingdom
Myricx Bio is a technology company.
Myricx Bio is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.
Myricx Bio has raised $126.0M across 2 funding rounds.
Myricx Bio has raised $126.0M in total across 2 funding rounds.
Myricx Bio has raised $126.0M across 2 funding rounds. Most recently, it raised $120.0M Series A in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $120M Series A | Abingworth, MAX Klement | Atlas Venture, Brandon Capital Partners, Forbion, Soffinova Partners, Sofinnova Investments, Westlake Village BioPartners | Announced |
| Nov 1, 2020 | $6M Seed | Soffinova Partners, Brandon Capital | Brandon Capital Partners, Sofinnova Investments, Westlake Village BioPartners | Announced |
Myricx Bio has raised $126.0M in total across 2 funding rounds.
Myricx Bio's investors include Abingworth, Max Klement, Atlas Venture, Brandon Capital Partners, Forbion, Soffinova Partners, Sofinnova Investments, Westlake Village BioPartners, Brandon Capital.
Myricx Bio is a UK-based biotechnology company headquartered in London, specializing in the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs) based on inhibitors of *N*-myristoyltransferases (NMT), targeting unmet needs in oncology.[1][2][3] It builds ADCs that deliver selective cytotoxic payloads to cancer cells, serving patients with solid tumors by addressing proteins essential for cancer survival, with preclinical data showing excellent efficacy and safety across multiple antigens and cancer types.[1][5] The company has demonstrated strong growth momentum, raising £4.5 million in seed financing in 2019, followed by a £90 million ($114 million) Series A in recent years, expanding teams, nominating a lead candidate, and planning human trials in 2026.[4][5][8][9]
Myricx Bio, originally launched as Myricx Pharma in 2019, emerged as a spin-out from Imperial College London and the Francis Crick Institute, translating over 15 years of pioneering NMT biology and chemistry research by its co-founders: Professor Ed Tate, Dr. Andrew Bell, and Dr. Roberto Solari.[4][5] The idea stemmed from breakthrough discoveries revealing NMT inhibition's unique mechanism for selective cancer cell killing, particularly effective in previously "undruggable" MYC-driven cancers, secured through exclusive licenses to key patents from the institutions.[4] Early traction came swiftly with £4.5 million seed funding from Sofinnova Partners and Brandon Capital Partners, enabling pipeline prioritization from Stevenage Bioscience Catalyst facilities; pivotal moments include recent awards like the 2025 Cancer Research Horizons Start-Up Achievement Recognition and team expansions post-Series A.[4][5][8]
Myricx rides the explosive growth of the ADC market, projected to revolutionize oncology by precisely delivering payloads to tumors while minimizing systemic toxicity, amid surging demand for next-generation payloads beyond auristatins and maytansinoids.[1][2][5] Timing is ideal as NMT inhibition unlocks MYC-driven cancers—historically undruggable—and preclinical successes align with regulatory momentum for ADCs, evidenced by recent approvals and investor enthusiasm (e.g., £90m Series A).[4][5][8] Market forces like rising solid tumor incidence and biotech funding recovery favor Myricx, influencing the ecosystem by validating NMT as a payload class, potentially inspiring competitors and accelerating innovation in targeted therapies.[5]
Myricx Bio stands on the brink of clinical-stage status, with its lead NMTi-ADC entering trials in 2026, further US expansion, and pipeline maturation poised to deliver transformative oncology options.[5][9] Trends like ADC payload diversification, AI-driven drug design, and global partnerships will propel its trajectory, potentially evolving it into a multi-asset leader challenging incumbents in solid tumors. As a London-headquartered innovator born from academic breakthroughs, Myricx exemplifies how novel biotech payloads can redefine cancer treatment precision.[1][5]